Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
RPRX
RPRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RPRX News
Royalty Pharma Partners with Johnson & Johnson in $500M R&D Deal
1d ago
seekingalpha
Royalty Pharma and Johnson & Johnson Sign $500 Million Co-Funding Agreement
1d ago
NASDAQ.COM
Royalty Pharma Partners with Johnson & Johnson for $500 Million R&D Agreement
1d ago
Newsfilter
Royalty Pharma Enters Agreement to Propel Development of JNJ-4804 for Autoimmune Disorders
1d ago
moomoo
Royalty Pharma Reveals $500 Million R&D Co-Funding Partnership with Johnson & Johnson for 2026-2027
1d ago
moomoo
VFLO Stock Price Analysis and ETF Dynamics
Mar 23 2026
NASDAQ.COM
Zymeworks Secures $250 Million Royalty Financing from Royalty Pharma
Mar 02 2026
NASDAQ.COM
Zymeworks Secures $250 Million Royalty-Backed Financing
Mar 02 2026
Newsfilter
Zymeworks Secures $250 Million Royalty-Backed Financing
Mar 02 2026
Yahoo Finance
Teva and Medincell's NDA for Long-Acting Olanzapine Accepted by FDA
Feb 21 2026
seekingalpha
Royalty Pharma Reports Landmark 2025 Earnings with Strong Growth and Strategic Developments
Feb 11 2026
seekingalpha
Royalty Pharma Releases 2026 Financial Guidance
Feb 11 2026
seekingalpha
Royalty Pharma Set to Announce Q4 Earnings on February 11
Feb 10 2026
seekingalpha
Royalty Pharma Set for Upcoming Dividend Payment
Feb 05 2026
NASDAQ.COM
Wall Street's Latest Rating Changes Overview
Jan 30 2026
CNBC
Teva and Royalty Pharma Strike $500 Million Funding Agreement
Jan 12 2026
Benzinga
Show More News
